Annual Revenue Comparison: BioMarin Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.

BioMarin's revenue soars, Taro faces decline: A decade in review.

__timestampBioMarin Pharmaceutical Inc.Taro Pharmaceutical Industries Ltd.
Wednesday, January 1, 2014751040000759285000
Thursday, January 1, 2015889895000862944000
Friday, January 1, 20161116854000950751000
Sunday, January 1, 20171313646000879387000
Monday, January 1, 20181491212000661913000
Tuesday, January 1, 20191704048000669893000
Wednesday, January 1, 20201860455000644769000
Friday, January 1, 20211846275000548970000
Saturday, January 1, 20222096039000561347000
Sunday, January 1, 20232419226000572952000
Monday, January 1, 20242853915000629182000
Loading chart...

Data in motion

A Decade of Revenue Growth: BioMarin vs. Taro

In the competitive landscape of pharmaceuticals, BioMarin Pharmaceutical Inc. and Taro Pharmaceutical Industries Ltd. have showcased distinct revenue trajectories over the past decade. From 2014 to 2023, BioMarin's revenue surged by over 220%, reflecting its robust growth strategy and successful product launches. In contrast, Taro's revenue experienced a decline of approximately 25%, highlighting challenges in market dynamics and competitive pressures.

Key Insights

  • BioMarin's Growth: Starting at $751 million in 2014, BioMarin's revenue reached a peak of $2.42 billion in 2023, marking a consistent upward trend.
  • Taro's Challenges: Taro's revenue, which was slightly higher than BioMarin's in 2014, decreased to $573 million by 2023, indicating a need for strategic realignment.

This comparison underscores the importance of innovation and market adaptation in the pharmaceutical industry, where growth and sustainability are paramount.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025